Charlène Trilleaud

Charlène Trilleaud

Auto-generated profile, based on publicly available information

Charlène Trilleaud

OSE Immunotherapeutics, Nantes, France

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2021 in Science Advances
Verified
Journal Article
Open access
PDF file
CTC. Trilleaud
C. Trilleaud
VGV. Gauttier
V. Gauttier
KBK. Biteau
K. Biteau
IGI. Girault
I. Girault
LBL. Belarif
L. Belarif
Nicolas PoirierNicolas Poirier
Nicolas Poirier
Agonistic proresolutive monoclonal antibody reverses chronic inflammation.

19 October 2020 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
VGVanessa Gauttier
Vanessa Gauttier
SPSabrina Pengam
Sabrina Pengam
JDJustine Durand
Justine Durand
KBKevin Biteau
Kevin Biteau
CMCaroline Mary
Caroline Mary
Nicolas PoirierNicolas Poirier
Nicolas Poirier
T cell exclusion causes resistance to cancer immunotherapies via immune checkpoint blockade (ICB). Myeloid cells contribute to resistance by expressing signal regulatory protein-α (SIRPα), an inhibitory membrane receptor that interacts with ubiquitous receptor CD47 to control macrophage phagocytosis in the tumor microenvironment. Although CD47/SIRPα-targeting drugs have been assessed in preclinical models, the therapeutic benefit of selectively blocking SIRPα, and not SIRPγ/CD47, in humans remains unknown. We report a potent synergy between selective SIRPα blockade and ICB in increasing memory T cell responses and reverting exclusion in syngeneic and orthotopic tumor models. Selective SIRPα blockade stimulated tumor nest T cell recruitment by restoring murine and human macrophage chemokine secretion and increased anti-tumor T cell responses by promoting tumor-antigen crosspresentation by dendritic cells. However, nonselective SIRPα/SIRPγ blockade targeting CD47 impaired human T cell activation, proliferation, and endothelial transmigration. Selective SIRPα inhibition opens an attractive avenue to overcoming ICB resistance in patients with elevated myeloid cell infiltration in solid tumors.

4 November 2026
Verified
Book Chapter
Closed access
PDF file
VGVanessa Gauttier
Vanessa Gauttier
CCCharles-Antoine Coupet
Charles-Antoine Coupet
CTCharlène Trilleaud
Charlène Trilleaud
IGIsabelle Girault
Isabelle Girault
AMAurore Morello
Aurore Morello